
GXO Logistics, Inc., the world’s largest pure-play contract logistics provider, continues its expansion in the healthcare logistics sector, announcing today that it has been selected by NHS England as the logistics partner for the delivery of home Faecal Immunochemical Test (FIT) kits for eligible participants in the bowel cancer screening programme across England.
Under the agreement, GXO will manage the delivery and distribution of FIT kits in collaboration with best-in-class partners: MAST, the world’s largest distributor of FIT tests, and RDi, a leading UK partner for end-to-end diagnostic kits.
GXO’s solutions are specifically designed for the complex and highly regulated needs of healthcare supply chains, and we are proud to have been selected by NHS England to deliver this important national programme. This new partnership underscores GXO’s continued investment and rapid growth in the healthcare sector and demonstrates how our capabilities increase productivity and resilience in a critical part of the UK economy and the NHS.
– said Gavin Williams, Managing Director, GXO UK and Ireland.
GXO is a leading global provider of logistics solutions for the healthcare industry. In 2025, GXO was selected by NHS Supply Chain as a new logistics partner under a new agreement and has also confirmed partnerships with companies including Siemens Healthineers in the United States and bioMérieux in Europe.
This agreement aligns with the NHS 10-year health plan to shift care from hospitals to community settings, with a continued focus on prevention. Home FIT test kits help identify individuals at risk of cancer who require further investigation, and their delivery is a vital component of the NHS England screening pathway. Our expertise will ensure that those who need a test receive it, and that the laboratories performing the tests have the equipment necessary to screen patients effectively.
– added Eric Finton James, Senior Director, Healthcare, GXO UK and Ireland.
By combining advanced logistics capabilities with a deep understanding of healthcare supply requirements, GXO will support NHS England’s growth to make screening more accessible and convenient for patients across the country. This partnership highlights the importance of timely prevention and early detection in improving health outcomes.
We have been committed to the bowel cancer screening programme since its inception in 2008, so RDi is proud to continue supporting the programme’s efforts to increase participation rates and eliminate inequalities.
– said David Cahill, CEO of RDi.
Iain McElarney, Innovation Manager at Mast, said: “Mast has been developing FIT solutions for bowel cancer screening across Europe since 2005 and is particularly proud to continue its collaboration with the English bowel cancer screening programme, providing participants with an excellent experience and introducing innovations in laboratory testing.”
Source: GXO Logistics








